# Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-ft819-clinical-activity-in-sle-without-the-use-of-conditioning-chemotherapy-at-the-2026-asgct-annual-meeting
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-05-11 12:30 EST
Original Source URL: https://ir.fatetherapeutics.com
## Summary

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR

## Article Body
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR
## Recent Company News
- 2026-06-01 12:30 EST — [Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting) — Source: Fate Therapeutics
- 2026-05-21 12:30 EST — [Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases](https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-presentations-at-2026-asco-and-eular-annual-meetings-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases) — Source: Fate Therapeutics
- 2026-05-13 12:30 EST — [Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Fate Therapeutics
- 2026-05-11 12:30 EST — [Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-ft819-clinical-activity-in-sle-without-the-use-of-conditioning-chemotherapy-at-the-2026-asgct-annual-meeting) — Source: Fate Therapeutics
- 2026-05-05 12:30 EST — [Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819](https://biopharmsignal.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819) — Source: Fate Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)